UNSPSC 51143703: Amitriptyline/chlordiazepoxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.

UNSPSC 51143703 Amitriptyline/chlordiazepoxide is a Commodity code that in recent state and local activity does not map cleanly to the pharmaceutical compounds its name suggests. State and local solicitations tagged with this code are actually procuring naloxone delivery systems, drug deactivation equipment, and broader pharmaceutical supply agreements rather than the specific drug combination the code nominally describes. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Work scoped under the code ranges from direct procurement of naloxone kits and safe drug disposal systems to RFIs exploring direct-to-manufacturer pharmacy benefit programs and multi-state cooperative contracts for generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers.

Recent activity concentrates in Florida and Minnesota, with Texas signaling exploratory interest through an RFI. Seminole County, Florida released IFB 60459723LAS on June 30, 2026 (with a due date of July 26, 2023 per the source) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program—a preliminary market-intelligence phase intended to inform future formal procurement strategy. MMCAP, administered by Minnesota's Department of Administration, issued an RFP (S1070000015802) due March 26, 2026 to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed across Minnesota, Oregon, and other participating state and local government facilities through three authorized wholesalers, with contract awards effective July 1, 2026. The MMCAP RFP weights price competitiveness at 75 percent and requires vendors to maintain $5 million commercial general liability coverage and comply with cGMP and Drug Supply Chain Security Act certifications.